152 related articles for article (PubMed ID: 26549294)
1. Ibrutinib: another weapon in our arsenal against lympho-proliferative disorders.
Cabras MG; Angelucci E
Expert Opin Pharmacother; 2015; 16(18):2715-8. PubMed ID: 26549294
[TBL] [Abstract][Full Text] [Related]
2. Ibrutinib in B lymphoid malignancies.
Smith MR
Expert Opin Pharmacother; 2015; 16(12):1879-87. PubMed ID: 26165513
[TBL] [Abstract][Full Text] [Related]
3. Ibrutinib.
Schwarzbich MA; Witzens-Harig M
Recent Results Cancer Res; 2014; 201():259-67. PubMed ID: 24756799
[TBL] [Abstract][Full Text] [Related]
4. Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignancies.
Gayko U; Fung M; Clow F; Sun S; Faust E; Price S; James D; Doyle M; Bari S; Zhuang SH
Ann N Y Acad Sci; 2015 Nov; 1358():82-94. PubMed ID: 26348626
[TBL] [Abstract][Full Text] [Related]
5. Rituximab and ibrutinib in the treatment of Waldenström's macroglobulinemia.
Grunenberg A; Buske C
Future Oncol; 2019 Aug; 15(23):2687-2697. PubMed ID: 31184501
[TBL] [Abstract][Full Text] [Related]
6. [Ibrutinib - new tool in hematologist hand, new challenges for internist].
Majcherek M; Dworacka M; Dworacki G
Wiad Lek; 2017; 70(1):92-95. PubMed ID: 28343201
[TBL] [Abstract][Full Text] [Related]
7. Imbruvica
Murthy V; Weaving S; Paneesha S
Br J Nurs; 2017 May; 26(10):S20-S25. PubMed ID: 28541116
[TBL] [Abstract][Full Text] [Related]
8. Targeting Bruton's tyrosine kinase with ibrutinib in B-cell malignancies.
Wang Y; Zhang LL; Champlin RE; Wang ML
Clin Pharmacol Ther; 2015 May; 97(5):455-68. PubMed ID: 25669675
[TBL] [Abstract][Full Text] [Related]
9. The clinical safety of ibrutinib in chronic lymphocytic leukemia.
Molica S
Expert Opin Drug Saf; 2015 Oct; 14(10):1621-9. PubMed ID: 26359217
[TBL] [Abstract][Full Text] [Related]
10. Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial.
Nastoupil LJ; Lunning MA; Vose JM; Schreeder MT; Siddiqi T; Flowers CR; Cohen JB; Burger JA; Wierda WG; O'Brien S; Sportelli P; Miskin HP; Purdom MA; Weiss MS; Fowler NH
Lancet Haematol; 2019 Feb; 6(2):e100-e109. PubMed ID: 30709431
[TBL] [Abstract][Full Text] [Related]
11. [Ibrutinib prescription in B-cell lymphoid neoplasms].
Dougé A; Ravinet A; Bay JO; Tournilhac O; Guièze R; Lemal R
Bull Cancer; 2016 Feb; 103(2):127-37. PubMed ID: 26822906
[TBL] [Abstract][Full Text] [Related]
12. Hodgkin Lymphoma Transformation of Chronic Lymphocytic Leukemia Under Ibrutinib Therapy: Chance Association or Therapy-related?
Sachanas S; Pangalis GA; Moschogiannis M; Yiakoumis X; Koulieris E; Tsirkinidis P; Kalpadakis C; Rontogianni D
Anticancer Res; 2017 Jun; 37(6):3277-3280. PubMed ID: 28551676
[TBL] [Abstract][Full Text] [Related]
13. Targets for Ibrutinib Beyond B Cell Malignancies.
Berglöf A; Hamasy A; Meinke S; Palma M; Krstic A; Månsson R; Kimby E; Österborg A; Smith CI
Scand J Immunol; 2015 Sep; 82(3):208-17. PubMed ID: 26111359
[TBL] [Abstract][Full Text] [Related]
14. Updates in prognostication and treatment of Waldenström's macroglobulinemia.
Advani P; Paulus A; Ailawadhi S
Hematol Oncol Stem Cell Ther; 2019 Dec; 12(4):179-188. PubMed ID: 31158330
[TBL] [Abstract][Full Text] [Related]
15. The emerging role of ibrutinib in the treatment of chronic lymphocytic leukemia.
Molica S
Expert Rev Hematol; 2013 Oct; 6(5):543-6. PubMed ID: 24083545
[TBL] [Abstract][Full Text] [Related]
16. ibrutinib (IMBRUVICA°) and Waldenström's macroglobulinaemia.
Prescrire Int; 2016 Oct; 25(175):232. PubMed ID: 30645823
[TBL] [Abstract][Full Text] [Related]
17. Functional Characterization of 22 CYP3A4 Protein Variants to Metabolize Ibrutinib In Vitro.
Xu RA; Wen J; Tang P; Wang C; Xie S; Zhang BW; Zhou Q; Cai JP; Hu GX
Basic Clin Pharmacol Toxicol; 2018 Apr; 122(4):383-387. PubMed ID: 29117640
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Bendamustine and Ibrutinib in Previously Untreated Patients With Chronic Lymphocytic Leukemia: Indirect Comparison.
Andrasiak I; Rybka J; Knopinska-Posluszny W; Wrobel T
Clin Lymphoma Myeloma Leuk; 2017 May; 17(5):268-273. PubMed ID: 28395851
[TBL] [Abstract][Full Text] [Related]
19. Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice.
Gribben JG; Bosch F; Cymbalista F; Geisler CH; Ghia P; Hillmen P; Moreno C; Stilgenbauer S
Br J Haematol; 2018 Mar; 180(5):666-679. PubMed ID: 29318593
[TBL] [Abstract][Full Text] [Related]
20. Ibrutinib (Imbruvica). Relapsed chronic lymphocytic leukaemia and mantle cell lymphoma: uncertain impact on survival.
January
Prescrire Int; 2016 Apr; 25(170):89-92. PubMed ID: 27183765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
